Of course, even though more detailed pharmacokinetics approaches should be needed, these data suggested J2 as a possible candidate drug for sensitization as combination with conventional anticancer drugs in HSP27 overexpressed lung cancer patients. This evidence concerns the gene HSPB1 and lung carcinoma.